RSNA: Non-calcified arterial plaque is associated with diabetes, high
systolic blood pressure and elevated "bad" cholesterol levels in
asymptomatic individuals, according to a new study published online in
the journal Radiology. Coronary artery disease (CAD) is the leading cause of death in men
and women worldwide, accounting for 17 million deaths annually. Current
treatment strategies focus on cardiovascular risk and serum cholesterol
levels rather than direct assessment of extent of disease in the
coronary arteries.
Plaque that forms in the arterial walls can restrict blood flow and,
in some cases, rupture, leading to potentially fatal heart attacks.
There is considerable evidence that calcified, or stable, plaque is less
prone to rupture than non-calcified, or soft, plaque. Intravascular
ultrasound can quantify non-calcified and calcified coronary artery
plaque, but it is invasive and unsuitable for screening purposes.
Coronary artery calcium (CAC) scoring with CT, a common noninvasive
option, measures how much calcified plaque a person has, but it doesn't
measure non-calcified plaque, and that's the component that tends to be
dangerous. Despite treatment for hypercholesterolemia (high levels of
cholesterol in the blood), CAC scores often paradoxically increase.
Thus, researchers have searched for other plaque measures that can
identify treatment response.
"Most information to date about coronary artery disease and
cardiovascular risk factors in asymptomatic individuals has been derived
from calcium scoring," said the study's lead author, David A. Bluemke,
M.D., Ph.D., from the NIH Clinical Center. "We hypothesized that risk
factors for the presence of non-calcified plaque may differ from those
for calcified plaque."
Coronary computed tomography angiography (CCTA) has emerged as a
viable screening option for plaque, including non-calcified plaque. CCTA
can capture the full anatomic map of the coronary arteries in a single
heartbeat with low radiation dose and provide a complete picture of the
total amount of plaque throughout the arteries of the heart.
For the study, Dr. Bluemke and colleagues used CCTA to assess the
relationship between calcified and non-calcified coronary plaque burden
in the coronary arteries and cardiovascular risk factors in low- to
moderate-risk asymptomatic individuals.
The researchers recruited 202 asymptomatic men and women over age 55
who were eligible for statin therapy. CCTA was performed using a
320-detector row CT scanner and an intravenous contrast agent. Coronary
wall thickness/plaque was evaluated, and analysis was performed to
determine the relationship between risk factors and plaque.
Controlling for all risk factors, total coronary plaque index was
greater in men than in women. Non-calcified plaque index was
significantly associated with greater systolic blood pressure, diabetes,
and elevated low-density lipoprotein (LDL) cholesterol level.
"These results highlight the potential of CCTA in quantifying plaque
burden to assess progression or regression of coronary artery disease in
low- to moderate-risk individuals," Dr. Bluemke said.